ID   ROCK1_HUMAN             Reviewed;        1354 AA.
AC   Q13464; B0YJ91; Q2KHM4; Q59GZ4;
DT   24-MAY-2004, integrated into UniProtKB/Swiss-Prot.
DT   01-NOV-1996, sequence version 1.
DT   12-OCT-2022, entry version 221.
DE   RecName: Full=Rho-associated protein kinase 1;
DE            EC=2.7.11.1 {ECO:0000269|PubMed:10436159, ECO:0000269|PubMed:10652353, ECO:0000269|PubMed:11018042, ECO:0000269|PubMed:23093407, ECO:0000269|PubMed:23355470};
DE   AltName: Full=Renal carcinoma antigen NY-REN-35;
DE   AltName: Full=Rho-associated, coiled-coil-containing protein kinase 1;
DE   AltName: Full=Rho-associated, coiled-coil-containing protein kinase I;
DE            Short=ROCK-I;
DE   AltName: Full=p160 ROCK-1;
DE            Short=p160ROCK;
GN   Name=ROCK1;
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia;
OC   Eutheria; Euarchontoglires; Primates; Haplorrhini; Catarrhini; Hominidae;
OC   Homo.
OX   NCBI_TaxID=9606;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [MRNA], PROTEIN SEQUENCE OF 187-195; 281-288; 465-473;
RP   818-828; 885-893 AND 934-945, FUNCTION, PHOSPHORYLATION, INTERACTION WITH
RP   RHOA, SUBCELLULAR LOCATION, AND TISSUE SPECIFICITY.
RC   TISSUE=Leukemia;
RX   PubMed=8617235; DOI=10.1002/j.1460-2075.1996.tb00539.x;
RA   Ishizaki T., Maekawa M., Fujisawa K., Okawa K., Iwamatsu A., Fujita A.,
RA   Watanabe N., Saito Y., Kakizuka A., Morii N., Narumiya S.;
RT   "The small GTP-binding protein Rho binds to and activates a 160 kDa Ser/Thr
RT   protein kinase homologous to myotonic dystrophy kinase.";
RL   EMBO J. 15:1885-1893(1996).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA].
RG   NHLBI resequencing and genotyping service (RS&G);
RL   Submitted (FEB-2007) to the EMBL/GenBank/DDBJ databases.
RN   [3]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA].
RX   PubMed=15489334; DOI=10.1101/gr.2596504;
RG   The MGC Project Team;
RT   "The status, quality, and expansion of the NIH full-length cDNA project:
RT   the Mammalian Gene Collection (MGC).";
RL   Genome Res. 14:2121-2127(2004).
RN   [4]
RP   PROTEIN SEQUENCE OF 2-13; 85-94; 327-334; 405-415 AND 546-563, CLEAVAGE OF
RP   INITIATOR METHIONINE, ACETYLATION AT SER-2, AND IDENTIFICATION BY MASS
RP   SPECTROMETRY.
RC   TISSUE=Embryonic kidney;
RA   Bienvenut W.V., Ramsay A., Leung H.Y.;
RL   Submitted (MAR-2009) to UniProtKB.
RN   [5]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] OF 323-1027.
RC   TISSUE=Brain;
RA   Totoki Y., Toyoda A., Takeda T., Sakaki Y., Tanaka A., Yokoyama S.,
RA   Ohara O., Nagase T., Kikuno R.F.;
RL   Submitted (MAR-2005) to the EMBL/GenBank/DDBJ databases.
RN   [6]
RP   ROLE IN SMOOTH MUSCLE CONTRACTION.
RX   PubMed=9722579; DOI=10.1074/jbc.273.36.23433;
RA   Van Eyk J.E., Arrell D.K., Foster D.B., Strauss J.D., Heinonen T.Y.,
RA   Furmaniak-Kazmierczak E., Cote G.P., Mak A.S.;
RT   "Different molecular mechanisms for Rho family GTPase-dependent, Ca2+-
RT   independent contraction of smooth muscle.";
RL   J. Biol. Chem. 273:23433-23439(1998).
RN   [7]
RP   IDENTIFICATION AS A RENAL CANCER ANTIGEN.
RC   TISSUE=Renal cell carcinoma;
RX   PubMed=10508479;
RX   DOI=10.1002/(sici)1097-0215(19991112)83:4<456::aid-ijc4>3.0.co;2-5;
RA   Scanlan M.J., Gordan J.D., Williamson B., Stockert E., Bander N.H.,
RA   Jongeneel C.V., Gure A.O., Jaeger D., Jaeger E., Knuth A., Chen Y.-T.,
RA   Old L.J.;
RT   "Antigens recognized by autologous antibody in patients with renal-cell
RT   carcinoma.";
RL   Int. J. Cancer 83:456-464(1999).
RN   [8]
RP   FUNCTION, CATALYTIC ACTIVITY, INTERACTION WITH LIMK1 AND LIMK2, AND
RP   INHIBITION BY Y-27632.
RX   PubMed=10436159; DOI=10.1126/science.285.5429.895;
RA   Maekawa M., Ishizaki T., Boku S., Watanabe N., Fujita A., Iwamatsu A.,
RA   Obinata T., Ohashi K., Mizuno K., Narumiya S.;
RT   "Signaling from Rho to the actin cytoskeleton through protein kinases ROCK
RT   and LIM-kinase.";
RL   Science 285:895-898(1999).
RN   [9]
RP   FUNCTION, CATALYTIC ACTIVITY, AND INTERACTION WITH LIMK1.
RX   PubMed=10652353; DOI=10.1074/jbc.275.5.3577;
RA   Ohashi K., Nagata K., Maekawa M., Ishizaki T., Narumiya S., Mizuno K.;
RT   "Rho-associated kinase ROCK activates LIM-kinase 1 by phosphorylation at
RT   threonine 508 within the activation loop.";
RL   J. Biol. Chem. 275:3577-3582(2000).
RN   [10]
RP   FUNCTION, CATALYTIC ACTIVITY, AND INTERACTION WITH LIMK2.
RX   PubMed=11018042; DOI=10.1074/jbc.m007074200;
RA   Sumi T., Matsumoto K., Nakamura T.;
RT   "Specific activation of LIM kinase 2 via phosphorylation of threonine 505
RT   by ROCK, a Rho-dependent protein kinase.";
RL   J. Biol. Chem. 276:670-676(2001).
RN   [11]
RP   CLEAVAGE BY CASPASE-3, MUTAGENESIS OF ASP-1113, INTERACTION WITH PPP1R12A,
RP   AND FUNCTION.
RX   PubMed=11283607; DOI=10.1038/35070019;
RA   Sebbagh M., Renvoize C., Hamelin J., Riche N., Bertoglio J., Breard J.;
RT   "Caspase-3-mediated cleavage of ROCK I induces MLC phosphorylation and
RT   apoptotic membrane blebbing.";
RL   Nat. Cell Biol. 3:346-352(2001).
RN   [12]
RP   INTERACTION WITH GEM.
RX   PubMed=11956230; DOI=10.1083/jcb.200111026;
RA   Ward Y., Yap S.-F., Ravichandran V., Matsumura F., Ito M., Spinelli B.,
RA   Kelly K.;
RT   "The GTP binding proteins Gem and Rad are negative regulators of the Rho-
RT   Rho kinase pathway.";
RL   J. Cell Biol. 157:291-302(2002).
RN   [13]
RP   INTERACTION WITH RHOE AND PPP1R12A, AND SUBCELLULAR LOCATION.
RX   PubMed=12773565; DOI=10.1128/mcb.23.12.4219-4229.2003;
RA   Riento K., Guasch R.M., Garg R., Jin B., Ridley A.J.;
RT   "RhoE binds to ROCK I and inhibits downstream signaling.";
RL   Mol. Cell. Biol. 23:4219-4229(2003).
RN   [14]
RP   REVIEW.
RX   PubMed=12778124; DOI=10.1038/nrm1128;
RA   Riento K., Ridley A.J.;
RT   "Rocks: multifunctional kinases in cell behaviour.";
RL   Nat. Rev. Mol. Cell Biol. 4:446-456(2003).
RN   [15]
RP   INTERACTION WITH TSG101.
RX   PubMed=17853893; DOI=10.1038/sj.emboj.7601850;
RA   Morita E., Sandrin V., Chung H.Y., Morham S.G., Gygi S.P., Rodesch C.K.,
RA   Sundquist W.I.;
RT   "Human ESCRT and ALIX proteins interact with proteins of the midbody and
RT   function in cytokinesis.";
RL   EMBO J. 26:4215-4227(2007).
RN   [16]
RP   FUNCTION, AND INTERACTION WITH DAPK3.
RX   PubMed=17158456; DOI=10.1074/jbc.m609990200;
RA   Hagerty L., Weitzel D.H., Chambers J., Fortner C.N., Brush M.H.,
RA   Loiselle D., Hosoya H., Haystead T.A.;
RT   "ROCK1 phosphorylates and activates zipper-interacting protein kinase.";
RL   J. Biol. Chem. 282:4884-4893(2007).
RN   [17]
RP   FUNCTION, INTERACTION WITH FHOD1, AND SUBCELLULAR LOCATION.
RX   PubMed=18694941; DOI=10.1074/jbc.m801800200;
RA   Hannemann S., Madrid R., Stastna J., Kitzing T., Gasteier J.,
RA   Schoenichen A., Bouchet J., Jimenez A., Geyer M., Grosse R., Benichou S.,
RA   Fackler O.T.;
RT   "The diaphanous-related formin FHOD1 associates with ROCK1 and promotes
RT   Src-dependent plasma membrane blebbing.";
RL   J. Biol. Chem. 283:27891-27903(2008).
RN   [18]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-1105, AND IDENTIFICATION BY
RP   MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Cervix carcinoma;
RX   PubMed=18691976; DOI=10.1016/j.molcel.2008.07.007;
RA   Daub H., Olsen J.V., Bairlein M., Gnad F., Oppermann F.S., Korner R.,
RA   Greff Z., Keri G., Stemmann O., Mann M.;
RT   "Kinase-selective enrichment enables quantitative phosphoproteomics of the
RT   kinome across the cell cycle.";
RL   Mol. Cell 31:438-448(2008).
RN   [19]
RP   FUNCTION, AND INTERACTION WITH PFN1.
RX   PubMed=18573880; DOI=10.1128/mcb.00079-08;
RA   Shao J., Welch W.J., Diprospero N.A., Diamond M.I.;
RT   "Phosphorylation of profilin by ROCK1 regulates polyglutamine
RT   aggregation.";
RL   Mol. Cell. Biol. 28:5196-5208(2008).
RN   [20]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Cervix carcinoma;
RX   PubMed=18669648; DOI=10.1073/pnas.0805139105;
RA   Dephoure N., Zhou C., Villen J., Beausoleil S.A., Bakalarski C.E.,
RA   Elledge S.J., Gygi S.P.;
RT   "A quantitative atlas of mitotic phosphorylation.";
RL   Proc. Natl. Acad. Sci. U.S.A. 105:10762-10767(2008).
RN   [21]
RP   FUNCTION, AND INTERACTION WITH JIP3.
RX   PubMed=19036714; DOI=10.1126/scisignal.1161938;
RA   Ongusaha P.P., Qi H.H., Raj L., Kim Y.B., Aaronson S.A., Davis R.J.,
RA   Shi Y., Liao J.K., Lee S.W.;
RT   "Identification of ROCK1 as an upstream activator of the JIP-3 to JNK
RT   signaling axis in response to UVB damage.";
RL   Sci. Signal. 1:RA14-RA14(2008).
RN   [22]
RP   FUNCTION.
RX   PubMed=19181962; DOI=10.1152/ajpheart.01038.2008;
RA   Kroll J., Epting D., Kern K., Dietz C.T., Feng Y., Hammes H.P., Wieland T.,
RA   Augustin H.G.;
RT   "Inhibition of Rho-dependent kinases ROCK I/II activates VEGF-driven
RT   retinal neovascularization and sprouting angiogenesis.";
RL   Am. J. Physiol. 296:H893-H899(2009).
RN   [23]
RP   FUNCTION, AND INTERACTION WITH PPP1R12A.
RX   PubMed=19131646; DOI=10.1161/circresaha.108.188524;
RA   Wang Y., Zheng X.R., Riddick N., Bryden M., Baur W., Zhang X., Surks H.K.;
RT   "ROCK isoform regulation of myosin phosphatase and contractility in
RT   vascular smooth muscle cells.";
RL   Circ. Res. 104:531-540(2009).
RN   [24]
RP   FUNCTION.
RX   PubMed=19997641; DOI=10.1371/journal.pone.0008190;
RA   Lock F.E., Hotchin N.A.;
RT   "Distinct roles for ROCK1 and ROCK2 in the regulation of keratinocyte
RT   differentiation.";
RL   PLoS ONE 4:E8190-E8190(2009).
RN   [25]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-1105, AND IDENTIFICATION BY
RP   MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Leukemic T-cell;
RX   PubMed=19690332; DOI=10.1126/scisignal.2000007;
RA   Mayya V., Lundgren D.H., Hwang S.-I., Rezaul K., Wu L., Eng J.K.,
RA   Rodionov V., Han D.K.;
RT   "Quantitative phosphoproteomic analysis of T cell receptor signaling
RT   reveals system-wide modulation of protein-protein interactions.";
RL   Sci. Signal. 2:RA46-RA46(2009).
RN   [26]
RP   ACETYLATION [LARGE SCALE ANALYSIS] AT LYS-647, AND IDENTIFICATION BY MASS
RP   SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=19608861; DOI=10.1126/science.1175371;
RA   Choudhary C., Kumar C., Gnad F., Nielsen M.L., Rehman M., Walther T.C.,
RA   Olsen J.V., Mann M.;
RT   "Lysine acetylation targets protein complexes and co-regulates major
RT   cellular functions.";
RL   Science 325:834-840(2009).
RN   [27]
RP   INTERACTION WITH CHORDC1.
RX   PubMed=20230755; DOI=10.1016/j.devcel.2009.12.020;
RA   Ferretti R., Palumbo V., Di Savino A., Velasco S., Sbroggio M.,
RA   Sportoletti P., Micale L., Turco E., Silengo L., Palumbo G., Hirsch E.,
RA   Teruya-Feldstein J., Bonaccorsi S., Pandolfi P.P., Gatti M., Tarone G.,
RA   Brancaccio M.;
RT   "Morgana/chp-1, a ROCK inhibitor involved in centrosome duplication and
RT   tumorigenesis.";
RL   Dev. Cell 18:486-495(2010).
RN   [28]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=21269460; DOI=10.1186/1752-0509-5-17;
RA   Burkard T.R., Planyavsky M., Kaupe I., Breitwieser F.P., Buerckstuemmer T.,
RA   Bennett K.L., Superti-Furga G., Colinge J.;
RT   "Initial characterization of the human central proteome.";
RL   BMC Syst. Biol. 5:17-17(2011).
RN   [29]
RP   FUNCTION, AND CLEAVAGE BY CASPASE-3.
RX   PubMed=21072057; DOI=10.1038/cdd.2010.140;
RA   Gabet A.S., Coulon S., Fricot A., Vandekerckhove J., Chang Y., Ribeil J.A.,
RA   Lordier L., Zermati Y., Asnafi V., Belaid Z., Debili N., Vainchenker W.,
RA   Varet B., Hermine O., Courtois G.;
RT   "Caspase-activated ROCK-1 allows erythroblast terminal maturation
RT   independently of cytokine-induced Rho signaling.";
RL   Cell Death Differ. 18:678-689(2011).
RN   [30]
RP   REVIEW.
RX   PubMed=20803696; DOI=10.1002/cm.20472;
RA   Amano M., Nakayama M., Kaibuchi K.;
RT   "Rho-kinase/ROCK: A key regulator of the cytoskeleton and cell polarity.";
RL   Cytoskeleton 67:545-554(2010).
RN   [31]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=21406692; DOI=10.1126/scisignal.2001570;
RA   Rigbolt K.T., Prokhorova T.A., Akimov V., Henningsen J., Johansen P.T.,
RA   Kratchmarova I., Kassem M., Mann M., Olsen J.V., Blagoev B.;
RT   "System-wide temporal characterization of the proteome and phosphoproteome
RT   of human embryonic stem cell differentiation.";
RL   Sci. Signal. 4:RS3-RS3(2011).
RN   [32]
RP   FUNCTION, AND CATALYTIC ACTIVITY.
RX   PubMed=23093407; DOI=10.1074/jbc.m112.394965;
RA   Schofield A.V., Steel R., Bernard O.;
RT   "Rho-associated coiled-coil kinase (ROCK) protein controls microtubule
RT   dynamics in a novel signaling pathway that regulates cell migration.";
RL   J. Biol. Chem. 287:43620-43629(2012).
RN   [33]
RP   INTERACTION WITH SHROOM3.
RX   PubMed=22493320; DOI=10.1091/mbc.e11-11-0937;
RA   Mohan S., Rizaldy R., Das D., Bauer R.J., Heroux A., Trakselis M.A.,
RA   Hildebrand J.D., VanDemark A.P.;
RT   "Structure of Shroom domain 2 reveals a three-segmented coiled-coil
RT   required for dimerization, Rock binding, and apical constriction.";
RL   Mol. Biol. Cell 23:2131-2142(2012).
RN   [34]
RP   ACETYLATION [LARGE SCALE ANALYSIS] AT SER-2, CLEAVAGE OF INITIATOR
RP   METHIONINE [LARGE SCALE ANALYSIS], AND IDENTIFICATION BY MASS SPECTROMETRY
RP   [LARGE SCALE ANALYSIS].
RX   PubMed=22814378; DOI=10.1073/pnas.1210303109;
RA   Van Damme P., Lasa M., Polevoda B., Gazquez C., Elosegui-Artola A.,
RA   Kim D.S., De Juan-Pardo E., Demeyer K., Hole K., Larrea E., Timmerman E.,
RA   Prieto J., Arnesen T., Sherman F., Gevaert K., Aldabe R.;
RT   "N-terminal acetylome analyses and functional insights of the N-terminal
RT   acetyltransferase NatB.";
RL   Proc. Natl. Acad. Sci. U.S.A. 109:12449-12454(2012).
RN   [35]
RP   FUNCTION, AND CATALYTIC ACTIVITY.
RX   PubMed=23355470; DOI=10.1074/jbc.m112.441048;
RA   Schofield A.V., Gamell C., Suryadinata R., Sarcevic B., Bernard O.;
RT   "Tubulin polymerization promoting protein 1 (Tppp1) phosphorylation by Rho-
RT   associated coiled-coil kinase (rock) and cyclin-dependent kinase 1 (Cdk1)
RT   inhibits microtubule dynamics to increase cell proliferation.";
RL   J. Biol. Chem. 288:7907-7917(2013).
RN   [36]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-1328, AND IDENTIFICATION BY
RP   MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Erythroleukemia;
RX   PubMed=23186163; DOI=10.1021/pr300630k;
RA   Zhou H., Di Palma S., Preisinger C., Peng M., Polat A.N., Heck A.J.,
RA   Mohammed S.;
RT   "Toward a comprehensive characterization of a human cancer cell
RT   phosphoproteome.";
RL   J. Proteome Res. 12:260-271(2013).
RN   [37]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Liver;
RX   PubMed=24275569; DOI=10.1016/j.jprot.2013.11.014;
RA   Bian Y., Song C., Cheng K., Dong M., Wang F., Huang J., Sun D., Wang L.,
RA   Ye M., Zou H.;
RT   "An enzyme assisted RP-RPLC approach for in-depth analysis of human liver
RT   phosphoproteome.";
RL   J. Proteomics 96:253-262(2014).
RN   [38]
RP   X-RAY CRYSTALLOGRAPHY (2.6 ANGSTROMS) OF 947-1015 IN COMPLEX WITH RHOA.
RX   PubMed=14660612; DOI=10.1074/jbc.m311911200;
RA   Dvorsky R., Blumenstein L., Vetter I.R., Ahmadian M.R.;
RT   "Structural insights into the interaction of ROCKI with the switch regions
RT   of RhoA.";
RL   J. Biol. Chem. 279:7098-7104(2004).
RN   [39]
RP   X-RAY CRYSTALLOGRAPHY (2.60 ANGSTROMS) OF 6-415, AND SUBUNIT.
RX   PubMed=16249185; DOI=10.1074/jbc.m508847200;
RA   Jacobs M., Hayakawa K., Swenson L., Bellon S., Fleming M., Taslimi P.,
RA   Doran J.;
RT   "The structure of dimeric ROCK I reveals the mechanism for ligand
RT   selectivity.";
RL   J. Biol. Chem. 281:260-268(2006).
RN   [40]
RP   VARIANTS [LARGE SCALE ANALYSIS] ASN-108; SER-773; PRO-1112; SER-1193;
RP   GLU-1217; GLN-1262 AND ARG-1264.
RX   PubMed=17344846; DOI=10.1038/nature05610;
RA   Greenman C., Stephens P., Smith R., Dalgliesh G.L., Hunter C., Bignell G.,
RA   Davies H., Teague J., Butler A., Stevens C., Edkins S., O'Meara S.,
RA   Vastrik I., Schmidt E.E., Avis T., Barthorpe S., Bhamra G., Buck G.,
RA   Choudhury B., Clements J., Cole J., Dicks E., Forbes S., Gray K.,
RA   Halliday K., Harrison R., Hills K., Hinton J., Jenkinson A., Jones D.,
RA   Menzies A., Mironenko T., Perry J., Raine K., Richardson D., Shepherd R.,
RA   Small A., Tofts C., Varian J., Webb T., West S., Widaa S., Yates A.,
RA   Cahill D.P., Louis D.N., Goldstraw P., Nicholson A.G., Brasseur F.,
RA   Looijenga L., Weber B.L., Chiew Y.-E., DeFazio A., Greaves M.F.,
RA   Green A.R., Campbell P., Birney E., Easton D.F., Chenevix-Trench G.,
RA   Tan M.-H., Khoo S.K., Teh B.T., Yuen S.T., Leung S.Y., Wooster R.,
RA   Futreal P.A., Stratton M.R.;
RT   "Patterns of somatic mutation in human cancer genomes.";
RL   Nature 446:153-158(2007).
CC   -!- FUNCTION: Protein kinase which is a key regulator of the actin
CC       cytoskeleton and cell polarity (PubMed:10436159, PubMed:10652353,
CC       PubMed:11018042, PubMed:11283607, PubMed:17158456, PubMed:18573880,
CC       PubMed:19131646, PubMed:8617235, PubMed:9722579). Involved in
CC       regulation of smooth muscle contraction, actin cytoskeleton
CC       organization, stress fiber and focal adhesion formation, neurite
CC       retraction, cell adhesion and motility via phosphorylation of DAPK3,
CC       GFAP, LIMK1, LIMK2, MYL9/MLC2, TPPP, PFN1 and PPP1R12A
CC       (PubMed:10436159, PubMed:10652353, PubMed:11018042, PubMed:11283607,
CC       PubMed:17158456, PubMed:18573880, PubMed:19131646, PubMed:8617235,
CC       PubMed:9722579, PubMed:23093407, PubMed:23355470). Phosphorylates FHOD1
CC       and acts synergistically with it to promote SRC-dependent non-apoptotic
CC       plasma membrane blebbing (PubMed:18694941). Phosphorylates JIP3 and
CC       regulates the recruitment of JNK to JIP3 upon UVB-induced stress
CC       (PubMed:19036714). Acts as a suppressor of inflammatory cell migration
CC       by regulating PTEN phosphorylation and stability (By similarity). Acts
CC       as a negative regulator of VEGF-induced angiogenic endothelial cell
CC       activation (PubMed:19181962). Required for centrosome positioning and
CC       centrosome-dependent exit from mitosis (By similarity). Plays a role in
CC       terminal erythroid differentiation (PubMed:21072057). Inhibits podocyte
CC       motility via regulation of actin cytoskeletal dynamics and
CC       phosphorylation of CFL1 (By similarity). Promotes keratinocyte terminal
CC       differentiation (PubMed:19997641). Involved in osteoblast compaction
CC       through the fibronectin fibrillogenesis cell-mediated matrix assembly
CC       process, essential for osteoblast mineralization (By similarity). May
CC       regulate closure of the eyelids and ventral body wall by inducing the
CC       assembly of actomyosin bundles (By similarity).
CC       {ECO:0000250|UniProtKB:P70335, ECO:0000250|UniProtKB:Q8MIT6,
CC       ECO:0000269|PubMed:10436159, ECO:0000269|PubMed:10652353,
CC       ECO:0000269|PubMed:11018042, ECO:0000269|PubMed:11283607,
CC       ECO:0000269|PubMed:17158456, ECO:0000269|PubMed:18573880,
CC       ECO:0000269|PubMed:18694941, ECO:0000269|PubMed:19036714,
CC       ECO:0000269|PubMed:19131646, ECO:0000269|PubMed:19181962,
CC       ECO:0000269|PubMed:19997641, ECO:0000269|PubMed:21072057,
CC       ECO:0000269|PubMed:23093407, ECO:0000269|PubMed:23355470,
CC       ECO:0000269|PubMed:8617235, ECO:0000269|PubMed:9722579}.
CC   -!- CATALYTIC ACTIVITY:
CC       Reaction=ATP + L-seryl-[protein] = ADP + H(+) + O-phospho-L-seryl-
CC         [protein]; Xref=Rhea:RHEA:17989, Rhea:RHEA-COMP:9863, Rhea:RHEA-
CC         COMP:11604, ChEBI:CHEBI:15378, ChEBI:CHEBI:29999, ChEBI:CHEBI:30616,
CC         ChEBI:CHEBI:83421, ChEBI:CHEBI:456216; EC=2.7.11.1;
CC         Evidence={ECO:0000269|PubMed:10436159, ECO:0000269|PubMed:10652353,
CC         ECO:0000269|PubMed:11018042, ECO:0000269|PubMed:23093407,
CC         ECO:0000269|PubMed:23355470};
CC       PhysiologicalDirection=left-to-right; Xref=Rhea:RHEA:17990;
CC         Evidence={ECO:0000269|PubMed:10436159, ECO:0000269|PubMed:10652353,
CC         ECO:0000269|PubMed:11018042, ECO:0000269|PubMed:23093407,
CC         ECO:0000269|PubMed:23355470};
CC   -!- CATALYTIC ACTIVITY:
CC       Reaction=ATP + L-threonyl-[protein] = ADP + H(+) + O-phospho-L-
CC         threonyl-[protein]; Xref=Rhea:RHEA:46608, Rhea:RHEA-COMP:11060,
CC         Rhea:RHEA-COMP:11605, ChEBI:CHEBI:15378, ChEBI:CHEBI:30013,
CC         ChEBI:CHEBI:30616, ChEBI:CHEBI:61977, ChEBI:CHEBI:456216;
CC         EC=2.7.11.1; Evidence={ECO:0000269|PubMed:10436159,
CC         ECO:0000269|PubMed:10652353, ECO:0000269|PubMed:11018042,
CC         ECO:0000269|PubMed:23093407, ECO:0000269|PubMed:23355470};
CC       PhysiologicalDirection=left-to-right; Xref=Rhea:RHEA:46609;
CC         Evidence={ECO:0000269|PubMed:10436159, ECO:0000269|PubMed:10652353,
CC         ECO:0000269|PubMed:11018042, ECO:0000269|PubMed:23093407,
CC         ECO:0000269|PubMed:23355470};
CC   -!- COFACTOR:
CC       Name=Mg(2+); Xref=ChEBI:CHEBI:18420;
CC   -!- ACTIVITY REGULATION: Activated by RHOA binding. Inhibited by Y-27632.
CC   -!- SUBUNIT: Homodimer. Interacts with RHOB, RHOC, MYLC2B and PTEN.
CC       Interacts with ITGB1BP1 (via N-terminus and PTB domain) (By
CC       similarity). Interacts with RHOA (activated by GTP), CHORDC1, DAPK3,
CC       GEM, JIP3, RHOE, PPP1R12A, PFN1, LIMK1, LIMK2 and TSG101. Interacts
CC       with FHOD1 in a Src-dependent manner. Interacts with SHROOM3
CC       (PubMed:22493320). {ECO:0000250|UniProtKB:P70335,
CC       ECO:0000269|PubMed:10436159, ECO:0000269|PubMed:10652353,
CC       ECO:0000269|PubMed:11018042, ECO:0000269|PubMed:11283607,
CC       ECO:0000269|PubMed:11956230, ECO:0000269|PubMed:12773565,
CC       ECO:0000269|PubMed:14660612, ECO:0000269|PubMed:16249185,
CC       ECO:0000269|PubMed:17158456, ECO:0000269|PubMed:17853893,
CC       ECO:0000269|PubMed:18573880, ECO:0000269|PubMed:18694941,
CC       ECO:0000269|PubMed:19036714, ECO:0000269|PubMed:19131646,
CC       ECO:0000269|PubMed:20230755, ECO:0000269|PubMed:22493320,
CC       ECO:0000269|PubMed:8617235}.
CC   -!- INTERACTION:
CC       Q13464; Q8IYR0: CFAP206; NbExp=3; IntAct=EBI-876651, EBI-749051;
CC       Q13464; Q86V42: FAM124A; NbExp=3; IntAct=EBI-876651, EBI-744506;
CC       Q13464; Q7Z6J6: FRMD5; NbExp=4; IntAct=EBI-876651, EBI-727282;
CC       Q13464; P25791: LMO2; NbExp=3; IntAct=EBI-876651, EBI-739696;
CC       Q13464; O15481: MAGEB4; NbExp=4; IntAct=EBI-876651, EBI-751857;
CC       Q13464; Q13203: MYBPH; NbExp=2; IntAct=EBI-876651, EBI-5655165;
CC       Q13464; Q9BUI4: POLR3C; NbExp=3; IntAct=EBI-876651, EBI-5452779;
CC       Q13464; P61586: RHOA; NbExp=4; IntAct=EBI-876651, EBI-446668;
CC       Q13464; Q99816: TSG101; NbExp=4; IntAct=EBI-876651, EBI-346882;
CC   -!- SUBCELLULAR LOCATION: Cytoplasm {ECO:0000269|PubMed:8617235}.
CC       Cytoplasm, cytoskeleton, microtubule organizing center, centrosome,
CC       centriole {ECO:0000250|UniProtKB:P70335}. Golgi apparatus membrane
CC       {ECO:0000269|PubMed:12773565}; Peripheral membrane protein
CC       {ECO:0000269|PubMed:12773565}. Cell projection, bleb
CC       {ECO:0000269|PubMed:18694941}. Cytoplasm, cytoskeleton
CC       {ECO:0000250|UniProtKB:P70335}. Cell membrane
CC       {ECO:0000250|UniProtKB:P70335}. Cell projection, lamellipodium
CC       {ECO:0000250|UniProtKB:P70335}. Cell projection, ruffle
CC       {ECO:0000250|UniProtKB:P70335}. Note=A small proportion is associated
CC       with Golgi membranes (PubMed:12773565). Associated with the mother
CC       centriole and an intercentriolar linker (By similarity). Colocalizes
CC       with ITGB1BP1 and ITGB1 at the cell membrane predominantly in
CC       lamellipodia and membrane ruffles, but also in retraction fibers (By
CC       similarity). Localizes at the cell membrane in an ITGB1BP1-dependent
CC       manner (By similarity). {ECO:0000250|UniProtKB:P70335,
CC       ECO:0000269|PubMed:12773565}.
CC   -!- TISSUE SPECIFICITY: Detected in blood platelets.
CC       {ECO:0000269|PubMed:8617235}.
CC   -!- DOMAIN: The C-terminal auto-inhibitory domain interferes with kinase
CC       activity. RHOA binding leads to a conformation change and activation of
CC       the kinase. Truncated ROCK1 is constitutively activated.
CC   -!- PTM: Autophosphorylated on serine and threonine residues.
CC       {ECO:0000269|PubMed:8617235}.
CC   -!- PTM: Cleaved by caspase-3 during apoptosis. This leads to constitutive
CC       activation of the kinase and membrane blebbing.
CC   -!- SIMILARITY: Belongs to the protein kinase superfamily. AGC Ser/Thr
CC       protein kinase family. {ECO:0000305}.
CC   ---------------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution (CC BY 4.0) License
CC   ---------------------------------------------------------------------------
DR   EMBL; U43195; AAB02814.1; -; mRNA.
DR   EMBL; EF445027; ACA06069.1; -; Genomic_DNA.
DR   EMBL; BC113114; AAI13115.1; -; mRNA.
DR   EMBL; AB208965; BAD92202.1; -; mRNA.
DR   CCDS; CCDS11870.2; -.
DR   PIR; S69211; S69211.
DR   RefSeq; NP_005397.1; NM_005406.2.
DR   PDB; 1S1C; X-ray; 2.60 A; X/Y=947-1015.
DR   PDB; 2ESM; X-ray; 3.20 A; A/B=6-415.
DR   PDB; 2ETK; X-ray; 2.96 A; A/B=6-415.
DR   PDB; 2ETR; X-ray; 2.60 A; A/B=6-415.
DR   PDB; 2V55; X-ray; 3.70 A; A/C=1-406.
DR   PDB; 3D9V; X-ray; 3.30 A; A/B=6-415.
DR   PDB; 3NCZ; X-ray; 3.00 A; A/B/C/D=6-415.
DR   PDB; 3NDM; X-ray; 3.30 A; A/B/C/D=6-415.
DR   PDB; 3O0Z; X-ray; 2.33 A; A/B/C/D=535-700.
DR   PDB; 3TV7; X-ray; 2.75 A; A/B/C/D=6-415.
DR   PDB; 3TWJ; X-ray; 2.90 A; A/B/C/D=6-415.
DR   PDB; 3V8S; X-ray; 2.29 A; A/B/C/D=6-415.
DR   PDB; 4L2W; X-ray; 2.49 A; A/B/C/D=834-914.
DR   PDB; 4W7P; X-ray; 2.80 A; A/B/C/D=2-410.
DR   PDB; 4YVC; X-ray; 3.20 A; A/B=6-415.
DR   PDB; 4YVE; X-ray; 3.40 A; A/B=6-415.
DR   PDB; 5BML; X-ray; 2.95 A; A/B=6-415.
DR   PDB; 5F5P; X-ray; 3.57 A; C/D/E/F=834-913.
DR   PDB; 5HVU; X-ray; 2.80 A; A/B=6-415.
DR   PDB; 5KKS; X-ray; 3.30 A; A/B=6-415.
DR   PDB; 5KKT; X-ray; 2.80 A; A/B=6-415.
DR   PDB; 5UZJ; X-ray; 3.30 A; A/B=6-415.
DR   PDB; 5WNE; X-ray; 2.60 A; A/B/C/D=6-415.
DR   PDB; 5WNF; X-ray; 2.45 A; A/B/C/D=6-415.
DR   PDB; 5WNG; X-ray; 2.90 A; A/B/C/D=6-415.
DR   PDB; 5WNH; X-ray; 3.10 A; A/B/C/D=6-415.
DR   PDB; 6E9W; X-ray; 2.96 A; A/B=6-415.
DR   PDB; 7JOU; X-ray; 3.32 A; A=6-415.
DR   PDBsum; 1S1C; -.
DR   PDBsum; 2ESM; -.
DR   PDBsum; 2ETK; -.
DR   PDBsum; 2ETR; -.
DR   PDBsum; 2V55; -.
DR   PDBsum; 3D9V; -.
DR   PDBsum; 3NCZ; -.
DR   PDBsum; 3NDM; -.
DR   PDBsum; 3O0Z; -.
DR   PDBsum; 3TV7; -.
DR   PDBsum; 3TWJ; -.
DR   PDBsum; 3V8S; -.
DR   PDBsum; 4L2W; -.
DR   PDBsum; 4W7P; -.
DR   PDBsum; 4YVC; -.
DR   PDBsum; 4YVE; -.
DR   PDBsum; 5BML; -.
DR   PDBsum; 5F5P; -.
DR   PDBsum; 5HVU; -.
DR   PDBsum; 5KKS; -.
DR   PDBsum; 5KKT; -.
DR   PDBsum; 5UZJ; -.
DR   PDBsum; 5WNE; -.
DR   PDBsum; 5WNF; -.
DR   PDBsum; 5WNG; -.
DR   PDBsum; 5WNH; -.
DR   PDBsum; 6E9W; -.
DR   PDBsum; 7JOU; -.
DR   AlphaFoldDB; Q13464; -.
DR   SMR; Q13464; -.
DR   BioGRID; 112020; 122.
DR   CORUM; Q13464; -.
DR   DIP; DIP-35645N; -.
DR   ELM; Q13464; -.
DR   IntAct; Q13464; 39.
DR   MINT; Q13464; -.
DR   STRING; 9606.ENSP00000382697; -.
DR   BindingDB; Q13464; -.
DR   ChEMBL; CHEMBL3231; -.
DR   DrugBank; DB07876; (S)-2-METHYL-1-[(4-METHYL-5-ISOQUINOLINE)SULFONYL]-HOMOPIPERAZINE.
DR   DrugBank; DB16703; Belumosudil.
DR   DrugBank; DB08162; Fasudil.
DR   DrugBank; DB04707; Hydroxyfasudil.
DR   DrugBank; DB13931; Netarsudil.
DR   DrugBank; DB13165; Ripasudil.
DR   DrugBank; DB08756; Y-27632.
DR   DrugCentral; Q13464; -.
DR   GuidetoPHARMACOLOGY; 1503; -.
DR   GlyGen; Q13464; 1 site, 1 O-linked glycan (1 site).
DR   iPTMnet; Q13464; -.
DR   MetOSite; Q13464; -.
DR   PhosphoSitePlus; Q13464; -.
DR   SwissPalm; Q13464; -.
DR   BioMuta; ROCK1; -.
DR   DMDM; 47605999; -.
DR   EPD; Q13464; -.
DR   jPOST; Q13464; -.
DR   MassIVE; Q13464; -.
DR   MaxQB; Q13464; -.
DR   PaxDb; Q13464; -.
DR   PeptideAtlas; Q13464; -.
DR   PRIDE; Q13464; -.
DR   ProteomicsDB; 59461; -.
DR   Antibodypedia; 1128; 704 antibodies from 45 providers.
DR   DNASU; 6093; -.
DR   Ensembl; ENST00000399799.3; ENSP00000382697.1; ENSG00000067900.8.
DR   GeneID; 6093; -.
DR   KEGG; hsa:6093; -.
DR   MANE-Select; ENST00000399799.3; ENSP00000382697.1; NM_005406.3; NP_005397.1.
DR   UCSC; uc002kte.4; human.
DR   CTD; 6093; -.
DR   DisGeNET; 6093; -.
DR   GeneCards; ROCK1; -.
DR   HGNC; HGNC:10251; ROCK1.
DR   HPA; ENSG00000067900; Low tissue specificity.
DR   MIM; 601702; gene.
DR   neXtProt; NX_Q13464; -.
DR   OpenTargets; ENSG00000067900; -.
DR   PharmGKB; PA34623; -.
DR   VEuPathDB; HostDB:ENSG00000067900; -.
DR   eggNOG; KOG0612; Eukaryota.
DR   GeneTree; ENSGT01030000234517; -.
DR   HOGENOM; CLU_000288_140_0_1; -.
DR   InParanoid; Q13464; -.
DR   OMA; XETLATQ; -.
DR   OrthoDB; 759391at2759; -.
DR   PhylomeDB; Q13464; -.
DR   TreeFam; TF313551; -.
DR   PathwayCommons; Q13464; -.
DR   Reactome; R-HSA-111465; Apoptotic cleavage of cellular proteins.
DR   Reactome; R-HSA-3928662; EPHB-mediated forward signaling.
DR   Reactome; R-HSA-3928663; EPHA-mediated growth cone collapse.
DR   Reactome; R-HSA-416482; G alpha (12/13) signalling events.
DR   Reactome; R-HSA-416572; Sema4D induced cell migration and growth-cone collapse.
DR   Reactome; R-HSA-4420097; VEGFA-VEGFR2 Pathway.
DR   Reactome; R-HSA-5627117; RHO GTPases Activate ROCKs.
DR   Reactome; R-HSA-6798695; Neutrophil degranulation.
DR   Reactome; R-HSA-8980692; RHOA GTPase cycle.
DR   Reactome; R-HSA-9013026; RHOB GTPase cycle.
DR   Reactome; R-HSA-9013106; RHOC GTPase cycle.
DR   Reactome; R-HSA-9013407; RHOH GTPase cycle.
DR   Reactome; R-HSA-9013422; RHOBTB1 GTPase cycle.
DR   Reactome; R-HSA-9679191; Potential therapeutics for SARS.
DR   Reactome; R-HSA-9696264; RND3 GTPase cycle.
DR   SABIO-RK; Q13464; -.
DR   SignaLink; Q13464; -.
DR   SIGNOR; Q13464; -.
DR   BioGRID-ORCS; 6093; 24 hits in 1109 CRISPR screens.
DR   ChiTaRS; ROCK1; human.
DR   EvolutionaryTrace; Q13464; -.
DR   GeneWiki; ROCK1; -.
DR   GenomeRNAi; 6093; -.
DR   Pharos; Q13464; Tclin.
DR   PRO; PR:Q13464; -.
DR   Proteomes; UP000005640; Chromosome 18.
DR   RNAct; Q13464; protein.
DR   Bgee; ENSG00000067900; Expressed in calcaneal tendon and 95 other tissues.
DR   ExpressionAtlas; Q13464; baseline and differential.
DR   Genevisible; Q13464; HS.
DR   GO; GO:0032059; C:bleb; IEA:UniProtKB-SubCell.
DR   GO; GO:0005814; C:centriole; IEA:UniProtKB-SubCell.
DR   GO; GO:0005737; C:cytoplasm; IBA:GO_Central.
DR   GO; GO:0010494; C:cytoplasmic stress granule; ISS:ARUK-UCL.
DR   GO; GO:0005856; C:cytoskeleton; ISS:UniProtKB.
DR   GO; GO:0005829; C:cytosol; TAS:Reactome.
DR   GO; GO:0005576; C:extracellular region; TAS:Reactome.
DR   GO; GO:0000139; C:Golgi membrane; IEA:UniProtKB-SubCell.
DR   GO; GO:0030027; C:lamellipodium; ISS:UniProtKB.
DR   GO; GO:0005886; C:plasma membrane; ISS:UniProtKB.
DR   GO; GO:0001726; C:ruffle; ISS:UniProtKB.
DR   GO; GO:0034774; C:secretory granule lumen; TAS:Reactome.
DR   GO; GO:0019828; F:aspartic-type endopeptidase inhibitor activity; IMP:ARUK-UCL.
DR   GO; GO:0005524; F:ATP binding; IEA:UniProtKB-KW.
DR   GO; GO:0046872; F:metal ion binding; IEA:UniProtKB-KW.
DR   GO; GO:0004672; F:protein kinase activity; TAS:ProtInc.
DR   GO; GO:0106310; F:protein serine kinase activity; IEA:RHEA.
DR   GO; GO:0004674; F:protein serine/threonine kinase activity; IDA:UniProtKB.
DR   GO; GO:0072518; F:Rho-dependent protein serine/threonine kinase activity; IDA:UniProtKB.
DR   GO; GO:0031267; F:small GTPase binding; IEA:InterPro.
DR   GO; GO:0048156; F:tau protein binding; NAS:ARUK-UCL.
DR   GO; GO:0050321; F:tau-protein kinase activity; NAS:ARUK-UCL.
DR   GO; GO:0030036; P:actin cytoskeleton organization; ISS:BHF-UCL.
DR   GO; GO:0031032; P:actomyosin structure organization; IBA:GO_Central.
DR   GO; GO:0003180; P:aortic valve morphogenesis; ISS:BHF-UCL.
DR   GO; GO:0003383; P:apical constriction; IEA:Ensembl.
DR   GO; GO:0032060; P:bleb assembly; IEA:Ensembl.
DR   GO; GO:0097746; P:blood vessel diameter maintenance; ISS:ARUK-UCL.
DR   GO; GO:0030866; P:cortical actin cytoskeleton organization; IMP:UniProtKB.
DR   GO; GO:0048598; P:embryonic morphogenesis; IBA:GO_Central.
DR   GO; GO:0001837; P:epithelial to mesenchymal transition; ISS:BHF-UCL.
DR   GO; GO:0007249; P:I-kappaB kinase/NF-kappaB signaling; IMP:UniProtKB.
DR   GO; GO:0007159; P:leukocyte cell-cell adhesion; IDA:BHF-UCL.
DR   GO; GO:0050900; P:leukocyte migration; IDA:BHF-UCL.
DR   GO; GO:0050901; P:leukocyte tethering or rolling; IDA:BHF-UCL.
DR   GO; GO:0022614; P:membrane to membrane docking; IDA:BHF-UCL.
DR   GO; GO:0000281; P:mitotic cytokinesis; IBA:GO_Central.
DR   GO; GO:0097049; P:motor neuron apoptotic process; IEA:Ensembl.
DR   GO; GO:0061157; P:mRNA destabilization; ISS:ARUK-UCL.
DR   GO; GO:0051451; P:myoblast migration; ISS:UniProtKB.
DR   GO; GO:1902992; P:negative regulation of amyloid precursor protein catabolic process; IMP:ARUK-UCL.
DR   GO; GO:1902430; P:negative regulation of amyloid-beta formation; IMP:ARUK-UCL.
DR   GO; GO:0016525; P:negative regulation of angiogenesis; IMP:UniProtKB.
DR   GO; GO:1903347; P:negative regulation of bicellular tight junction assembly; IGI:UniProtKB.
DR   GO; GO:0070168; P:negative regulation of biomineral tissue development; ISS:BHF-UCL.
DR   GO; GO:0051045; P:negative regulation of membrane protein ectodomain proteolysis; TAS:ARUK-UCL.
DR   GO; GO:2000672; P:negative regulation of motor neuron apoptotic process; IEA:Ensembl.
DR   GO; GO:0035509; P:negative regulation of myosin-light-chain-phosphatase activity; IMP:UniProtKB.
DR   GO; GO:0042326; P:negative regulation of phosphorylation; ISS:UniProtKB.
DR   GO; GO:0032091; P:negative regulation of protein binding; IDA:UniProtKB.
DR   GO; GO:0140058; P:neuron projection arborization; IGI:ARUK-UCL.
DR   GO; GO:0031175; P:neuron projection development; IGI:ARUK-UCL.
DR   GO; GO:0018105; P:peptidyl-serine phosphorylation; IDA:UniProtKB.
DR   GO; GO:0018107; P:peptidyl-threonine phosphorylation; IBA:GO_Central.
DR   GO; GO:0090521; P:podocyte cell migration; ISS:UniProtKB.
DR   GO; GO:1900223; P:positive regulation of amyloid-beta clearance; IGI:ARUK-UCL.
DR   GO; GO:0010508; P:positive regulation of autophagy; IGI:ARUK-UCL.
DR   GO; GO:0010613; P:positive regulation of cardiac muscle hypertrophy; IMP:ARUK-UCL.
DR   GO; GO:1905205; P:positive regulation of connective tissue replacement; IMP:ARUK-UCL.
DR   GO; GO:0035306; P:positive regulation of dephosphorylation; IMP:ARUK-UCL.
DR   GO; GO:0051894; P:positive regulation of focal adhesion assembly; ISS:UniProtKB.
DR   GO; GO:0010628; P:positive regulation of gene expression; IMP:ARUK-UCL.
DR   GO; GO:0043410; P:positive regulation of MAPK cascade; IMP:ARUK-UCL.
DR   GO; GO:0010922; P:positive regulation of phosphatase activity; IMP:ARUK-UCL.
DR   GO; GO:0072659; P:protein localization to plasma membrane; IMP:UniProtKB.
DR   GO; GO:0006468; P:protein phosphorylation; IDA:UniProtKB.
DR   GO; GO:0032956; P:regulation of actin cytoskeleton organization; IDA:UniProtKB.
DR   GO; GO:1902003; P:regulation of amyloid-beta formation; TAS:ARUK-UCL.
DR   GO; GO:0110061; P:regulation of angiotensin-activated signaling pathway; IMP:ARUK-UCL.
DR   GO; GO:0010506; P:regulation of autophagy; TAS:ARUK-UCL.
DR   GO; GO:0030155; P:regulation of cell adhesion; TAS:UniProtKB.
DR   GO; GO:1901888; P:regulation of cell junction assembly; IBA:GO_Central.
DR   GO; GO:0030334; P:regulation of cell migration; IDA:UniProtKB.
DR   GO; GO:2000145; P:regulation of cell motility; TAS:UniProtKB.
DR   GO; GO:2000114; P:regulation of establishment of cell polarity; TAS:UniProtKB.
DR   GO; GO:1903140; P:regulation of establishment of endothelial barrier; IMP:UniProtKB.
DR   GO; GO:0051893; P:regulation of focal adhesion assembly; TAS:UniProtKB.
DR   GO; GO:0045616; P:regulation of keratinocyte differentiation; IMP:UniProtKB.
DR   GO; GO:0070507; P:regulation of microtubule cytoskeleton organization; IDA:UniProtKB.
DR   GO; GO:0045664; P:regulation of neuron differentiation; IGI:ARUK-UCL.
DR   GO; GO:0051492; P:regulation of stress fiber assembly; TAS:UniProtKB.
DR   GO; GO:1900242; P:regulation of synaptic vesicle endocytosis; IGI:ARUK-UCL.
DR   GO; GO:1990776; P:response to angiotensin; ISS:ARUK-UCL.
DR   GO; GO:0071559; P:response to transforming growth factor beta; ISS:ARUK-UCL.
DR   GO; GO:0007266; P:Rho protein signal transduction; IGI:ARUK-UCL.
DR   GO; GO:0007165; P:signal transduction; TAS:ProtInc.
DR   GO; GO:0006939; P:smooth muscle contraction; TAS:UniProtKB.
DR   CDD; cd00029; C1; 1.
DR   CDD; cd11639; HR1_ROCK1; 1.
DR   DisProt; DP02365; -.
DR   Gene3D; 2.30.29.30; -; 1.
DR   InterPro; IPR000961; AGC-kinase_C.
DR   InterPro; IPR046349; C1-like_sf.
DR   InterPro; IPR011072; HR1_rho-bd.
DR   InterPro; IPR011009; Kinase-like_dom_sf.
DR   InterPro; IPR002219; PE/DAG-bd.
DR   InterPro; IPR011993; PH-like_dom_sf.
DR   InterPro; IPR001849; PH_domain.
DR   InterPro; IPR000719; Prot_kinase_dom.
DR   InterPro; IPR017441; Protein_kinase_ATP_BS.
DR   InterPro; IPR020684; ROCK1/ROCK2.
DR   InterPro; IPR037310; ROCK1_HR1.
DR   InterPro; IPR015008; ROCK_Rho-bd_dom.
DR   InterPro; IPR008271; Ser/Thr_kinase_AS.
DR   Pfam; PF00069; Pkinase; 1.
DR   Pfam; PF08912; Rho_Binding; 1.
DR   PIRSF; PIRSF037568; Rho_kinase; 1.
DR   SMART; SM00109; C1; 1.
DR   SMART; SM00233; PH; 1.
DR   SMART; SM00133; S_TK_X; 1.
DR   SMART; SM00220; S_TKc; 1.
DR   SUPFAM; SSF56112; SSF56112; 1.
DR   SUPFAM; SSF57889; SSF57889; 1.
DR   PROSITE; PS51285; AGC_KINASE_CTER; 1.
DR   PROSITE; PS50003; PH_DOMAIN; 1.
DR   PROSITE; PS00107; PROTEIN_KINASE_ATP; 1.
DR   PROSITE; PS50011; PROTEIN_KINASE_DOM; 1.
DR   PROSITE; PS00108; PROTEIN_KINASE_ST; 1.
DR   PROSITE; PS51860; REM_1; 1.
DR   PROSITE; PS51859; RHO_BD; 1.
DR   PROSITE; PS50081; ZF_DAG_PE_2; 1.
PE   1: Evidence at protein level;
KW   3D-structure; Acetylation; Apoptosis; ATP-binding; Cell membrane;
KW   Cell projection; Coiled coil; Cytoplasm; Cytoskeleton;
KW   Direct protein sequencing; Golgi apparatus; Kinase; Magnesium; Membrane;
KW   Metal-binding; Nucleotide-binding; Phosphoprotein; Reference proteome;
KW   Serine/threonine-protein kinase; Transferase; Zinc; Zinc-finger.
FT   INIT_MET        1
FT                   /note="Removed"
FT                   /evidence="ECO:0000269|Ref.4, ECO:0007744|PubMed:22814378"
FT   CHAIN           2..1354
FT                   /note="Rho-associated protein kinase 1"
FT                   /id="PRO_0000086619"
FT   DOMAIN          76..338
FT                   /note="Protein kinase"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00159"
FT   DOMAIN          341..409
FT                   /note="AGC-kinase C-terminal"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00618"
FT   DOMAIN          479..556
FT                   /note="REM-1"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU01207"
FT   DOMAIN          949..1015
FT                   /note="RhoBD"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU01206"
FT   DOMAIN          1118..1317
FT                   /note="PH"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00145"
FT   ZN_FING         1228..1281
FT                   /note="Phorbol-ester/DAG-type"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00226"
FT   REGION          368..727
FT                   /note="Interaction with FHOD1"
FT                   /evidence="ECO:0000269|PubMed:18694941"
FT   REGION          707..946
FT                   /note="SHROOM3 binding"
FT                   /evidence="ECO:0000269|PubMed:22493320"
FT   REGION          998..1010
FT                   /note="RHOA binding"
FT   REGION          1115..1354
FT                   /note="Auto-inhibitory"
FT   REGION          1320..1354
FT                   /note="Disordered"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   COILED          422..692
FT                   /evidence="ECO:0000255"
FT   COILED          1011..1102
FT                   /evidence="ECO:0000255"
FT   COMPBIAS        1326..1354
FT                   /note="Polar residues"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   ACT_SITE        198
FT                   /note="Proton acceptor"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00159,
FT                   ECO:0000255|PROSITE-ProRule:PRU10027"
FT   BINDING         82..90
FT                   /ligand="ATP"
FT                   /ligand_id="ChEBI:CHEBI:30616"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00159"
FT   BINDING         105
FT                   /ligand="ATP"
FT                   /ligand_id="ChEBI:CHEBI:30616"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00159"
FT   SITE            1113..1114
FT                   /note="Cleavage; by caspase-3"
FT   MOD_RES         2
FT                   /note="N-acetylserine"
FT                   /evidence="ECO:0000269|Ref.4, ECO:0007744|PubMed:22814378"
FT   MOD_RES         647
FT                   /note="N6-acetyllysine"
FT                   /evidence="ECO:0007744|PubMed:19608861"
FT   MOD_RES         1105
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0007744|PubMed:18691976,
FT                   ECO:0007744|PubMed:19690332"
FT   MOD_RES         1108
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0000250|UniProtKB:P70335"
FT   MOD_RES         1328
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0007744|PubMed:23186163"
FT   VARIANT         108
FT                   /note="S -> N (in dbSNP:rs55811609)"
FT                   /evidence="ECO:0000269|PubMed:17344846"
FT                   /id="VAR_041055"
FT   VARIANT         773
FT                   /note="T -> S (in dbSNP:rs45562542)"
FT                   /evidence="ECO:0000269|PubMed:17344846"
FT                   /id="VAR_041056"
FT   VARIANT         1112
FT                   /note="T -> P (in dbSNP:rs35881519)"
FT                   /evidence="ECO:0000269|PubMed:17344846"
FT                   /id="VAR_041057"
FT   VARIANT         1193
FT                   /note="P -> S (in a lung neuroendocrine carcinoma sample;
FT                   somatic mutation; dbSNP:rs1057520015)"
FT                   /evidence="ECO:0000269|PubMed:17344846"
FT                   /id="VAR_041058"
FT   VARIANT         1217
FT                   /note="Q -> E (in dbSNP:rs2847092)"
FT                   /evidence="ECO:0000269|PubMed:17344846"
FT                   /id="VAR_041059"
FT   VARIANT         1262
FT                   /note="R -> Q (in dbSNP:rs1045142)"
FT                   /evidence="ECO:0000269|PubMed:17344846"
FT                   /id="VAR_041060"
FT   VARIANT         1264
FT                   /note="C -> R (in dbSNP:rs2663698)"
FT                   /evidence="ECO:0000269|PubMed:17344846"
FT                   /id="VAR_041061"
FT   MUTAGEN         1113
FT                   /note="D->A: Abolishes cleavage by caspase-3."
FT                   /evidence="ECO:0000269|PubMed:11283607"
FT   CONFLICT        170
FT                   /note="V -> A (in Ref. 3; AAI13115)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        197
FT                   /note="R -> G (in Ref. 3; AAI13115)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        220
FT                   /note="C -> R (in Ref. 3; AAI13115)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        323..325
FT                   /note="RLG -> GTR (in Ref. 5; BAD92202)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        521
FT                   /note="D -> N (in Ref. 3; AAI13115)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        965
FT                   /note="K -> R (in Ref. 3; AAI13115)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        1354
FT                   /note="S -> R (in Ref. 2; ACA06069)"
FT                   /evidence="ECO:0000305"
FT   HELIX           9..19
FT                   /evidence="ECO:0007829|PDB:3V8S"
FT   STRAND          24..26
FT                   /evidence="ECO:0007829|PDB:5WNG"
FT   HELIX           27..41
FT                   /evidence="ECO:0007829|PDB:3V8S"
FT   HELIX           44..47
FT                   /evidence="ECO:0007829|PDB:3V8S"
FT   HELIX           50..69
FT                   /evidence="ECO:0007829|PDB:3V8S"
FT   HELIX           73..75
FT                   /evidence="ECO:0007829|PDB:3V8S"
FT   STRAND          76..84
FT                   /evidence="ECO:0007829|PDB:3V8S"
FT   STRAND          86..95
FT                   /evidence="ECO:0007829|PDB:3V8S"
FT   TURN            96..98
FT                   /evidence="ECO:0007829|PDB:3V8S"
FT   STRAND          101..108
FT                   /evidence="ECO:0007829|PDB:3V8S"
FT   HELIX           109..114
FT                   /evidence="ECO:0007829|PDB:3V8S"
FT   HELIX           121..130
FT                   /evidence="ECO:0007829|PDB:3V8S"
FT   STRAND          139..144
FT                   /evidence="ECO:0007829|PDB:3V8S"
FT   STRAND          146..153
FT                   /evidence="ECO:0007829|PDB:3V8S"
FT   STRAND          157..160
FT                   /evidence="ECO:0007829|PDB:3NDM"
FT   HELIX           161..167
FT                   /evidence="ECO:0007829|PDB:3V8S"
FT   HELIX           172..191
FT                   /evidence="ECO:0007829|PDB:3V8S"
FT   HELIX           201..203
FT                   /evidence="ECO:0007829|PDB:3V8S"
FT   STRAND          204..206
FT                   /evidence="ECO:0007829|PDB:3V8S"
FT   STRAND          212..214
FT                   /evidence="ECO:0007829|PDB:3V8S"
FT   HELIX           217..219
FT                   /evidence="ECO:0007829|PDB:5KKS"
FT   STRAND          227..230
FT                   /evidence="ECO:0007829|PDB:3V8S"
FT   HELIX           238..240
FT                   /evidence="ECO:0007829|PDB:3V8S"
FT   HELIX           243..247
FT                   /evidence="ECO:0007829|PDB:3V8S"
FT   TURN            248..252
FT                   /evidence="ECO:0007829|PDB:3V8S"
FT   STRAND          254..256
FT                   /evidence="ECO:0007829|PDB:3V8S"
FT   HELIX           258..273
FT                   /evidence="ECO:0007829|PDB:3V8S"
FT   HELIX           283..291
FT                   /evidence="ECO:0007829|PDB:3V8S"
FT   HELIX           293..296
FT                   /evidence="ECO:0007829|PDB:3V8S"
FT   HELIX           307..316
FT                   /evidence="ECO:0007829|PDB:3V8S"
FT   HELIX           320..322
FT                   /evidence="ECO:0007829|PDB:3V8S"
FT   TURN            324..327
FT                   /evidence="ECO:0007829|PDB:5WNF"
FT   HELIX           329..333
FT                   /evidence="ECO:0007829|PDB:3V8S"
FT   HELIX           336..338
FT                   /evidence="ECO:0007829|PDB:3V8S"
FT   TURN            345..347
FT                   /evidence="ECO:0007829|PDB:5WNE"
FT   HELIX           348..350
FT                   /evidence="ECO:0007829|PDB:3V8S"
FT   HELIX           365..367
FT                   /evidence="ECO:0007829|PDB:3NCZ"
FT   HELIX           392..394
FT                   /evidence="ECO:0007829|PDB:3V8S"
FT   STRAND          399..402
FT                   /evidence="ECO:0007829|PDB:2ETR"
FT   HELIX           535..540
FT                   /evidence="ECO:0007829|PDB:3O0Z"
FT   HELIX           544..691
FT                   /evidence="ECO:0007829|PDB:3O0Z"
FT   HELIX           840..902
FT                   /evidence="ECO:0007829|PDB:4L2W"
FT   HELIX           947..982
FT                   /evidence="ECO:0007829|PDB:1S1C"
FT   HELIX           984..1011
FT                   /evidence="ECO:0007829|PDB:1S1C"
SQ   SEQUENCE   1354 AA;  158175 MW;  93078CBB009A6F27 CRC64;
     MSTGDSFETR FEKMDNLLRD PKSEVNSDCL LDGLDALVYD LDFPALRKNK NIDNFLSRYK
     DTINKIRDLR MKAEDYEVVK VIGRGAFGEV QLVRHKSTRK VYAMKLLSKF EMIKRSDSAF
     FWEERDIMAF ANSPWVVQLF YAFQDDRYLY MVMEYMPGGD LVNLMSNYDV PEKWARFYTA
     EVVLALDAIH SMGFIHRDVK PDNMLLDKSG HLKLADFGTC MKMNKEGMVR CDTAVGTPDY
     ISPEVLKSQG GDGYYGRECD WWSVGVFLYE MLVGDTPFYA DSLVGTYSKI MNHKNSLTFP
     DDNDISKEAK NLICAFLTDR EVRLGRNGVE EIKRHLFFKN DQWAWETLRD TVAPVVPDLS
     SDIDTSNFDD LEEDKGEEET FPIPKAFVGN QLPFVGFTYY SNRRYLSSAN PNDNRTSSNA
     DKSLQESLQK TIYKLEEQLH NEMQLKDEME QKCRTSNIKL DKIMKELDEE GNQRRNLEST
     VSQIEKEKML LQHRINEYQR KAEQENEKRR NVENEVSTLK DQLEDLKKVS QNSQLANEKL
     SQLQKQLEEA NDLLRTESDT AVRLRKSHTE MSKSISQLES LNRELQERNR ILENSKSQTD
     KDYYQLQAIL EAERRDRGHD SEMIGDLQAR ITSLQEEVKH LKHNLEKVEG ERKEAQDMLN
     HSEKEKNNLE IDLNYKLKSL QQRLEQEVNE HKVTKARLTD KHQSIEEAKS VAMCEMEKKL
     KEEREAREKA ENRVVQIEKQ CSMLDVDLKQ SQQKLEHLTG NKERMEDEVK NLTLQLEQES
     NKRLLLQNEL KTQAFEADNL KGLEKQMKQE INTLLEAKRL LEFELAQLTK QYRGNEGQMR
     ELQDQLEAEQ YFSTLYKTQV KELKEEIEEK NRENLKKIQE LQNEKETLAT QLDLAETKAE
     SEQLARGLLE EQYFELTQES KKAASRNRQE ITDKDHTVSR LEEANSMLTK DIEILRRENE
     ELTEKMKKAE EEYKLEKEEE ISNLKAAFEK NINTERTLKT QAVNKLAEIM NRKDFKIDRK
     KANTQDLRKK EKENRKLQLE LNQEREKFNQ MVVKHQKELN DMQAQLVEEC AHRNELQMQL
     ASKESDIEQL RAKLLDLSDS TSVASFPSAD ETDGNLPESR IEGWLSVPNR GNIKRYGWKK
     QYVVVSSKKI LFYNDEQDKE QSNPSMVLDI DKLFHVRPVT QGDVYRAETE EIPKIFQILY
     ANEGECRKDV EMEPVQQAEK TNFQNHKGHE FIPTLYHFPA NCDACAKPLW HVFKPPPALE
     CRRCHVKCHR DHLDKKEDLI CPCKVSYDVT SARDMLLLAC SQDEQKKWVT HLVKKIPKNP
     PSGFVRASPR TLSTRSTANQ SFRKVVKNTS GKTS
//
